|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||9.10 - 9.35|
|52-week range||8.47 - 13.89|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||14.75|
NEW YORK and SAINT-PRIEST, France, April 24, 2018 (GLOBE NEWSWIRE) -- Biom'up (BUP.PA), a specialist in surgical hemostasis, today announced that its intensive training program to train surgeons in the use of its lead product HEMOBLAST Bellows is on track and has reached the Company’s objective of 200 trained surgeons ahead of the launch of HEMOBLAST Bellows in mid-2018. To prepare the surgical community for the imminent launch of HEMOBLAST Bellows, Biom’up ran 6 highly attended training sessions for surgeons in the U.S. and Europe, which were led by the Company’s experts in collaboration with key opinion leaders in surgical hemostasis.
2017 results underscore focus on establishing a strong financial foundation as basis for commercial strategy going forward A total of €100 million raised through 2017 to date Marketing approval lead product ...
SAINT-PRIEST, France, March 26, 2018-- Biom’ up, specialist of surgical hemostasis, today announced the appointment, effective May 2, 2018, of Thierry Darnis as Global Vice President Manufacturing and ...